ATP synthase F1 subunit deltaGenealiases: ATP5D · MC5DN5
Q-omics provides the consensus-scored ATP5F1D profile across patient tissues and cancer cell-line models. ATP5F1D expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ATP5F1D is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, ATP5F1D protein abundance shows 37,677 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, LUSC, and GBM as cancer lineages where ATP5F1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5F1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5F1D survival associations across molecular data types. ATP5F1D RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5F1D RNA expression–survival associations across cancer types. High ATP5F1D expression shows unfavorable associations in UCS, ACC, LUAD, KICH and COAD, but favorable associations in KIRP. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ATP5F1D RNA expression.
This table summarizes ATP5F1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATP5F1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5F1D shows lower tumor expression in THCA and higher tumor expression in LUSC, LIHC, KICH, CHOL and STAD. The LUSC box plot shows higher ATP5F1D RNA expression in tumor versus normal tissue (log2 FC = +0.659, t-test p < 0.001).
This table shows molecular features associated with ATP5F1D in patient tissues and cancer cell lines. In patient samples, ATP5F1D shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP5F1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
